161 related articles for article (PubMed ID: 31130605)
1. Molecular Docking and Molecular Dynamics (MD) Simulation of Human Anti-Complement Factor H (CFH) Antibody Ab42 and CFH Polypeptide.
Yang B; Lin SJ; Ren JY; Liu T; Wang YM; Li CM; Xu WW; He YW; Zheng WH; Zhao J; Yuan XH; Liao HX
Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31130605
[TBL] [Abstract][Full Text] [Related]
2. Antibody recognition of complement factor H reveals a flexible loop involved in atypical hemolytic uremic syndrome pathogenesis.
Yokoo T; Tanabe A; Yoshida Y; Caaveiro JMM; Nakakido M; Ikeda Y; Fujimura Y; Matsumoto M; Entzminger K; Maruyama T; Okumura CJ; Nangaku M; Tsumoto K
J Biol Chem; 2022 Jun; 298(6):101962. PubMed ID: 35452676
[TBL] [Abstract][Full Text] [Related]
3. Molecular Characterization of Two Monoclonal Antibodies against the Same Epitope on B-Cell Receptor Associated Protein 31.
Kim WT; Shin S; Hwang HJ; Kim MK; Jung HS; Park H; Ryu CJ
PLoS One; 2016; 11(12):e0167527. PubMed ID: 27907150
[TBL] [Abstract][Full Text] [Related]
4. A Therapeutic Antibody for Cancer, Derived from Single Human B Cells.
Bushey RT; Moody MA; Nicely NL; Haynes BF; Alam SM; Keir ST; Bentley RC; Roy Choudhury K; Gottlin EB; Campa MJ; Liao HX; Patz EF
Cell Rep; 2016 May; 15(7):1505-1513. PubMed ID: 27160908
[TBL] [Abstract][Full Text] [Related]
5. The major autoantibody epitope on factor H in atypical hemolytic uremic syndrome is structurally different from its homologous site in factor H-related protein 1, supporting a novel model for induction of autoimmunity in this disease.
Bhattacharjee A; Reuter S; Trojnár E; Kolodziejczyk R; Seeberger H; Hyvärinen S; Uzonyi B; Szilágyi Á; Prohászka Z; Goldman A; Józsi M; Jokiranta TS
J Biol Chem; 2015 Apr; 290(15):9500-10. PubMed ID: 25659429
[TBL] [Abstract][Full Text] [Related]
6. Roles of the respective loops at complementarity determining region on the antigen-antibody recognition.
Osajima T; Hoshino T
Comput Biol Chem; 2016 Oct; 64():368-383. PubMed ID: 27591792
[TBL] [Abstract][Full Text] [Related]
7. Characterization of a high-affinity human antibody with a disulfide bridge in the third complementarity-determining region of the heavy chain.
Almagro JC; Raghunathan G; Beil E; Janecki DJ; Chen Q; Dinh T; LaCombe A; Connor J; Ware M; Kim PH; Swanson RV; Fransson J
J Mol Recognit; 2012 Mar; 25(3):125-35. PubMed ID: 22407976
[TBL] [Abstract][Full Text] [Related]
8. Computational Tools for Aiding Rational Antibody Design.
Krawczyk K; Dunbar J; Deane CM
Methods Mol Biol; 2017; 1529():399-416. PubMed ID: 27914064
[TBL] [Abstract][Full Text] [Related]
9. An antibody-based biomarker discovery method by mass spectrometry sequencing of complementarity determining regions.
Dekker LJ; Zeneyedpour L; Brouwer E; van Duijn MM; Sillevis Smitt PA; Luider TM
Anal Bioanal Chem; 2011 Jan; 399(3):1081-91. PubMed ID: 21107826
[TBL] [Abstract][Full Text] [Related]
10. Restricted diversity of antigen binding residues of antibodies revealed by computational alanine scanning of 227 antibody-antigen complexes.
Robin G; Sato Y; Desplancq D; Rochel N; Weiss E; Martineau P
J Mol Biol; 2014 Nov; 426(22):3729-3743. PubMed ID: 25174334
[TBL] [Abstract][Full Text] [Related]
11. Interaction between the antigen and antibody is controlled by the constant domains: normal mode dynamics of the HEL-HyHEL-10 complex.
Adachi M; Kurihara Y; Nojima H; Takeda-Shitaka M; Kamiya K; Umeyama H
Protein Sci; 2003 Oct; 12(10):2125-31. PubMed ID: 14500870
[TBL] [Abstract][Full Text] [Related]
12. A novel antibody humanization method based on epitopes scanning and molecular dynamics simulation.
Zhang D; Chen CF; Zhao BB; Gong LL; Jin WJ; Liu JJ; Wang JF; Wang TT; Yuan XH; He YW
PLoS One; 2013; 8(11):e80636. PubMed ID: 24278299
[TBL] [Abstract][Full Text] [Related]
13. A computational approach for studying antibody-antigen interactions without prior structural information: the anti-testosterone binding antibody as a case study.
Koivuniemi A; Takkinen K; Nevanen T
Proteins; 2017 Feb; 85(2):322-331. PubMed ID: 27936519
[TBL] [Abstract][Full Text] [Related]
14. Computational and statistical study on the molecular interaction between antigen and antibody.
Osajima T; Suzuki M; Neya S; Hoshino T
J Mol Graph Model; 2014 Sep; 53():128-139. PubMed ID: 25123651
[TBL] [Abstract][Full Text] [Related]
15. Downsizing antibodies: Towards complementarity-determining region (CDR)-based peptide mimetics.
Van Holsbeeck K; Martins JC; Ballet S
Bioorg Chem; 2022 Feb; 119():105563. PubMed ID: 34942468
[TBL] [Abstract][Full Text] [Related]
16. HIV glycoprotein 41 and complement factor H interact with each other and share functional as well as antigenic homology.
Pintér C; Siccardi AG; Lopalco L; Longhi R; Clivio A
AIDS Res Hum Retroviruses; 1995 Aug; 11(8):971-80. PubMed ID: 7492444
[TBL] [Abstract][Full Text] [Related]
17. Interaction of anti-HIV type 1 antibody 2F5 with phospholipid bilayers and its relevance for the mechanism of virus neutralization.
Maeso R; Huarte N; Julien JP; Kunert R; Pai EF; Nieva JL
AIDS Res Hum Retroviruses; 2011 Aug; 27(8):863-76. PubMed ID: 21142698
[TBL] [Abstract][Full Text] [Related]
18. Collagen type II is recognized by a pathogenic antibody through germline encoded structures.
Böiers U; Lanig H; Sehnert B; Holmdahl R; Burkhardt H
Eur J Immunol; 2008 Oct; 38(10):2784-95. PubMed ID: 18825755
[TBL] [Abstract][Full Text] [Related]
19. Complement Factor H Antibodies from Lung Cancer Patients Induce Complement-Dependent Lysis of Tumor Cells, Suggesting a Novel Immunotherapeutic Strategy.
Campa MJ; Gottlin EB; Bushey RT; Patz EF
Cancer Immunol Res; 2015 Dec; 3(12):1325-32. PubMed ID: 26216416
[TBL] [Abstract][Full Text] [Related]
20. Toward rational antibody design: recent advancements in molecular dynamics simulations.
Yamashita T
Int Immunol; 2018 Apr; 30(4):133-140. PubMed ID: 29346652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
